Burosumab-twza for Tumor-Induced Osteomalacia: Suzanne Jan de Beur, MD

In this interview with i3 Health, Suzanne Jan de Beur, MD, discusses the recent approval of burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), for patients with tumor-induced osteomalacia (TIO) whose tumors are unable to be localized or resected. Dr. Jan de Beur, lead investigator of one of the phase 2 clinical trials on which the approval was based, explains the challenges involved in diagnosing and treating TIO and discusses the significance of the approval of burosumab-twza for pati...

Continue reading

Tumor-Induced Osteomalacia: Burosumab-twza Approved

The FDA has approved burosumab-twza (Crysvita®, Ultragenyx Pharmaceutical, Inc.), a fully human monoclonal antibody, for the treatment of patients aged two and older with tumor-induced osteomalacia (TIO) whose tumors are unable to be located or removed. A rare condition, TIO develops when tumors secrete high levels of fibroblast growth factor 23 (FGF23), a peptide hormone–like substance which lowers phosphate levels, thereby weakening and softening the bones. Patients with TIO can experience bon...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.